S

Soluventis GmbH

50 employees

This company is developing a new class of oligonucleotide therapeutics based on its proprietary platform technology.

Basic info

Sectors

Biotechnology
Therapeutics

Date founded

2009

Funding rounds raised

S

Soluventis GmbH raised undisclosed on February 1, 2011

Investors: Mey Capital Matrix GmbH

FAQ